|
CCDC25 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 1.65223390524716E-12 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
5.92725868386879E-12 |
| Normal-vs-Stage2 |
1.54278999999757E-05 |
| Normal-vs-Stage3 |
8.27427015792637E-12 |
| Normal-vs-Stage4 |
7.48845430109668E-13 |
| Stage1-vs-Stage2 |
5.048600E-01 |
| Stage1-vs-Stage3 |
1.982450E-01 |
| Stage1-vs-Stage4 |
6.335200E-03 |
| Stage2-vs-Stage3 |
1.479190E-01 |
| Stage2-vs-Stage4 |
1.920340E-02 |
| Stage3-vs-Stage4 |
1.942590E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
1.01030295240889E-14 |
| Normal-vs-AfricanAmerican |
5.425600E-04 |
| Normal-vs-Asian |
1.32220000503835E-08 |
| Caucasian-vs-AfricanAmerican |
2.318000E-01 |
| Caucasian-vs-Asian |
7.471400E-01 |
| AfricanAmerican-vs-Asian |
3.797800E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
4.177658219362E-12 |
| Normal-vs-Female |
2.07078798553084E-12 |
| Male-vs-Female |
2.093800E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
5.36148903051981E-12 |
| Normal-vs-Age(41-60Yrs) |
1.55889967601297E-10 |
| Normal-vs-Age(61-80Yrs) |
1.78269621287086E-11 |
| Normal-vs-Age(81-100Yrs) |
1.317950E-03 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
5.166800E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
6.073400E-01 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
6.323200E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
2.907800E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
5.145600E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
7.742400E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
2.899900E-02 |
| Classical-VS-Follicular |
6.736400E-01 |
| Classical-VS-Other |
8.417900E-02 |
| Classical-VS-Normal |
2.40574227206025E-12 |
| Tall-VS-Follicular |
1.667510E-02 |
| Tall-VS-Other |
5.023800E-01 |
| Tall-VS-Normal |
6.41630082398592E-11 |
| Follicular-VS-Other |
1.346560E-01 |
| Follicular-VS-Normal |
6.39150000036892E-07 |
| Other-VS-Normal |
1.361120E-04 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
3.10219960830693E-10 |
| Normal-vs-N1 |
4.83280082619331E-13 |
| N0-vs-N1 |
3.041300E-03 |
|
|
